Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals finds a new supporter: Great Point Partners Healthcare Fund

GW Pharmaceuticals finds a new supporter: Great Point Partners Healthcare Fund

GW Pharmaceuticals (AIM: GWP), which develops and manufactures a range of cannabinoid medicines announced that it had successfully placed 7.55 million shares at 78 pence per share – a 1 pence premium to the closing price yesterday.


The bulk of the placing was taken up by US Healthcare Fund, Great Point Partners, while M&G Investment Management took up enough stock to maintain its equity interest in the company.


The placing will raise gross proceeds of US$11.2 million (£6.6 million) for GW Pharmaceuticals, who said the funds would be used for additional clinical trials and research & development.


In addition, GW Pharmaceuticals issued to Great Point warrants to subscribe for approximately 3.776 million shares, 1.888 million of which have an exercise price of 105 pence per share, and the remaining 1.888 million have an exercise price of 175 pence per share.


The warrants can be exercised at any time prior to the fifth anniversary of their issue.


The new shares represent approximately 7.0 per cent of the Company's issued share capital prior to the subscription.


Following the placing, Great Point will hold 5.8% of GW Pharmaceuticals, while M&G will hold 10.8%.
Justin Gover, Managing Director of GW, said: 'We are pleased that such a prominent US healthcare fund has sought to take this significant equity stake in GW. Great Point's investment widens and internationalises GW's institutional shareholder base and reflects GW's emerging presence in the US market. The investment also serves to further enhance GW's strong cash position.'

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

1537236236_main-better-use.jpg
Tue
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
cancer
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use